Dual GLP-1/GIP receptor agonism with tirzepatide demonstrates impressive reduction in principal CKD risk factors including blood pressure, blood glucose, and weight when compared to GLP-1 receptor agonism alone [89,90]. This evidence concerns the gene GLP1R and chronic kidney disease.